CTX310 Lipid Disorder: Phase 1 Trial Shows Prom...

By HEOR Staff Writer

November 10, 2025

CTX310 Breakthrough in Lipid Disorder Treatment CTX310 is a significant advancement as the first-in-human Phase 1 trial of this
Koselugo EU Approval: A Milestone in Treating Plexiform Neurofibromas for Adu...
Eloralintide Obesity Treatment: Phase 2 Trial Reveals Significant Weight Loss...
Advancing Kidney Transplant Transparency Through Patient Involvement
Barriers to African Pharmaceutical Growth: Navigating Regulatory and Procurem...
Obesity Health Economics: Forecasting Trends and Costs in the US
AI Chatbot Delusions: Navigating the Risks of Validation in Mental Health
NICE Endorses Darolutamide Prostate Cancer Treatment for Improved Patient Access
FDA Cancer Trial Guidelines: Prioritizing Overall Survival for Patient-Center...
Navigating Novo Nordisk Board Changes: Leadership for Growth and Strategy
Fabhalta Kidney Treatment Shows Promise in Slowing Disease Progression for Ig...
Keytruda Lung Cancer Treatment: Long-Term Survival Gains in NSCLC
Promising PSMA-Targeted Therapy Delays Prostate Cancer Progression